Clinical Laboratory Studies

What is its effectiveness and what does it refer to?

Vaccine type: mRNA
Effectiveness: 95% after the second dose in the prevention of symptomatic COVID-19.

No Does not contain egg, latex, or preservatives.

Who should or shouldn’t get the vaccine?
People who should receive the vaccine are those over 16 years old.
People who should not receive the vaccine are those who have a history of anaphylactic shock (severe allergy) or who are allergic to any component of this vaccine such as polyethylene glycol (PEG) or polysorbate.

How long will it take for me to be protected and what does it protect me from?
After 14 days of having the complete scheme (after the administration of the 2nd dose), the protection period is still under study. It protects us from serious COVID-19 or requiring hospitalization.

What is its effectiveness and what does it refer to?

Vaccine type: mRNA
Effectiveness: 94.5% after the second dose in the prevention of symptomatic COVID-19.

Does not contain egg, latex, or preservatives.

Who should or shouldn’t get the vaccine?
People who should receive the vaccine are those over 18 years old.
People who should not receive the vaccine are those who have a history of anaphylactic shock (severe allergy) or who are allergic to any component of this vaccine.

How long will it take for me to be protected and what does it protect me from?
After 14 days of having the complete scheme (after the administration of the 2nd dose), the protection period is still under study. It protects us from serious COVID-19 or requiring hospitalization.

What is its effectiveness and what does it refer to?

Vector-based vaccine.
Effectiveness: 72.0% in the prevention of symptomatic COVID-19.
85% in the prevention of severe COVID-19.

Does not contain egg, latex, or preservatives./strong>

What is its effectiveness and what does it refer to?

Adenovirus vector-based vaccine.
Effectiveness: 82% after the second dose in the prevention of symptomatic COVID-19.

Who should or shouldn’t get the vaccine?
People who should receive the vaccine are those over 18 years old.
People who should not receive the vaccine are those who have a history of anaphylactic shock (severe allergy) or who are allergic to any component of this vaccine.

How long will it take for me to be protected and what does it protect me from?
After 14 days of having the complete scheme (after the administration of the 2nd dose), the protection period is still under study. It protects us from serious COVID-19 or requiring hospitalization.

What is its effectiveness and what does it refer to?

Adenovirus vector-based vaccine.
Effectiveness: 92% after the second dose in the prevention of symptomatic COVID-19.

Who should or shouldn’t get the vaccine?
People who should receive the vaccine are those over 18 years old.
People who should not receive the vaccine are those who have a history of anaphylactic shock (severe allergy) or who are allergic to any component of this vaccine.

How long will it take for me to be protected and what does it protect me from?
After 14 days of having the complete scheme (after the administration of the 2nd dose), the protection period is still under study. It protects us from serious COVID-19 or requiring hospitalization.